Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Oasmia Enters New Important License Agreement for Paclical(R) Vet With Orion Corporation

Abstract:
Oasmia Pharmaceutical has entered into a license agreement with the Animal Health business of Orion Corporation, Finland, for the veterinary product Paclical(R) Vet (paclitaxel). The agreement covers the Nordic countries and Poland, the Czech Republic, Slovakia and Hungary. According to the agreement, Oasmia will receive EUR 2 million in up-front payments plus significant royalties on all sales. Orion obtains exclusive sales and distribution rights for the included territories.

Oasmia Enters New Important License Agreement for Paclical(R) Vet With Orion Corporation

UPPSALA, Sweden | Posted on April 1st, 2008

Paclical(R) Vet is a new cytostatic treatment for veterinary use, developed by Oasmia. Paclical(R) Vet is currently in clinical phase III. Another extensive international phase III study on mastocytoma in dogs will be initiated during spring 2008. The purpose is to ensure efficacy and safety in order to seek marketing authorisations for the product. If positive, Paclical(R) Vet will be the first cytostatic product to be registered for the treatment of dogs. Oasmia is responsible for all clinical development and registration of Paclical(R) Vet. Oasmia has in 2007 already established a licensing agreement with Orion Corporation regarding Paclical(R) for human use.

- "Orion Corporation has been leading in the Nordic region within animal health for a number of years. For Oasmia, they are an ideal partner in exploring this rapidly growing market. Together, we will be the first to explore this interesting field," comments Julian Aleksov, CEO of Oasmia.

- "Oncology is one of the key therapeutic areas for Orion. Paclical(R) Vet ideally complies with our strategy and our goal to provide our customers with innovative products for unmet medical needs, such as the challenge of to treat cancer. For us, this agreement with Oasmia means expanded collaboration with a company dedicated to innovative technologies and seeking new treatment approaches," says Satu Ahomaki, Senior Vice President heading the Animal Health business of Orion.

Today, there are 140 million dogs only in the EU and the US. The market, calculated as the number of dogs over six years old in the EU and the US of which 40 % will suffer from cancer, totals 1,5 billion USD. The Nordic region accounts for 3-4 % of the total world market. The market for Paclical(R) Vet is estimated to reach 350 to 650 million EUR in year 5 to 10 after registration.

About mastocytoma (Skin cancer)

Mastocytoma is a malignant form of cancer, originating from the mastocytom cells of the skin. The disease is graded I - III depending on the seriousness of the disease. This form of cancer accounts for approximately 20 % of all malignant skin tumours in dogs. Today, the most common form of treatment is surgery, although chemotherapy developed for human use is also used. Unfortunately, surgery as a treatment of grade III tumours is ineffective, and euthanization is often the only remaining alternative.

About Paclical(R) Vet

Paclical(R) Vet is a water soluble, solvent free nanoparticle formulation, based on the well-known cytotoxic substance paclitaxel. It's unique properties are based on Oasmia's nanotechnological formulation and micellar model XR-17, which is protected by international patents. The new Oasmia platform means that paclitaxel is water-soluble, that no premedication is necessary, infusion times can be shortened and infusion procedure can be made more effective.

####

About Oasmia Pharmaceutical
Oasmia Pharmaceutical AB develops second and third generation cancer drugs based on nanotechnology for human and veterinary use. The broad portfolio is focused on oncology and contains several promising products in clinical and pre-clinical phase. Oasmia cooperates with leading universities and other biotech companies to discover and optimize substances with a favourable safety profile and better efficacy. The company was founded in 1998 and is based in Uppsala, Sweden.

About Orion

Orion is a European pharmaceutical and diagnostics company which emphasises the development of innovative medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets pharmaceuticals for humans and animals, active pharmaceutical ingredients as well as diagnostic tests. Orion's clientele consists mainly of healthcare service providers and professionals. The Group's net sales in 2007 were EUR 683.6 million and in the end of 2007 there were 3 176 employees working for the Group. Orion's stocks are listed in OMX Nordic Exchange Helsinki.

For more information, please click here

Contacts:
Maria Lunden
+46(0)18-50-54-40

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Scientific breakthrough in rechargeable batteries: Researchers from Singapore and Québec Team Up to Develop Next-Generation Materials to Power Electronic Devices and Electric Vehicles February 28th, 2015

First detailed microscopy evidence of bacteria at the lower size limit of life: Berkeley Lab research provides comprehensive description of ultra-small bacteria February 28th, 2015

Leti to Offer Updates on Silicon Photonics Successes at OFC in LA February 27th, 2015

Moving molecule writes letters: Caging of molecules allows investigation of equilibrium thermodynamics February 27th, 2015

Nanomedicine

Untangling DNA with a droplet of water, a pipet and a polymer: With the 'rolling droplet technique,' a DNA-injected water droplet rolls like a ball over a platelet, sticking the DNA to the plate surface February 27th, 2015

Graphene shows potential as novel anti-cancer therapeutic strategy: University of Manchester scientists have used graphene to target and neutralise cancer stem cells while not harming other cells February 26th, 2015

Cutting-edge technology optimizes cancer therapy with nanomedicine drug combinations: UCLA bioengineers develop platform that offers personalized approach to treatment February 24th, 2015

Optical nanoantennas set the stage for a NEMS lab-on-a-chip revolution February 24th, 2015

Announcements

Scientific breakthrough in rechargeable batteries: Researchers from Singapore and Québec Team Up to Develop Next-Generation Materials to Power Electronic Devices and Electric Vehicles February 28th, 2015

First detailed microscopy evidence of bacteria at the lower size limit of life: Berkeley Lab research provides comprehensive description of ultra-small bacteria February 28th, 2015

Leti to Offer Updates on Silicon Photonics Successes at OFC in LA February 27th, 2015

Moving molecule writes letters: Caging of molecules allows investigation of equilibrium thermodynamics February 27th, 2015

Patents/IP/Tech Transfer/Licensing

New Paper-like Material Could Boost Electric Vehicle Batteries: Researchers create silicon nanofibers 100 times thinner than human hair for potential applications in batteries for electric cars and personal electronics February 20th, 2015

Nanotech Discoveries Move from Lab to Marketplace with Lintec Deal: Licensing Partnership Brings Together University Technology, New Richardson-Based Facility Directed by Alumni February 9th, 2015

Graphenea granted patent on graphene transfer February 9th, 2015

Toronto-based Environmental Technology Pioneer Green Earth Nano Science Expands in EU February 6th, 2015

Alliances/Partnerships/Distributorships

National Space Society and Space Frontier Foundation announce the formation of the Alliance for Space Development February 25th, 2015

European roadmap for graphene science and technology published February 25th, 2015

Silicon Catalyst Announces Partnership With imec to Support Semiconductor Start-Ups February 23rd, 2015

KIT Increases Commitment in Asia: DAAD Funds Two New Projects: Strategic Partnerships with Chinese Universities and Communi-cation Technologies Network February 22nd, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE